Wedbush Securities Has Upped Glaxosmithkline Plc (GSK) Stake By $423,464; Chubb Ltd (CB) Had 18 Analysts Last Week

November 15, 2017 - By Dolores Ford

Among 22 analysts covering The Chubb Corporation (NYSE:CB), 18 have Buy rating, 0 Sell and 4 Hold. Therefore 82% are positive. The Chubb Corporation had 45 analyst reports since July 24, 2015 according to SRatingsIntel. Sterne Agee CRT initiated Chubb Ltd (NYSE:CB) rating on Wednesday, August 26. Sterne Agee CRT has “Buy” rating and $42.0 target. The firm has “Buy” rating given on Thursday, June 1 by Keefe Bruyette & Woods. Robert W. Baird upgraded the shares of CB in report on Tuesday, December 15 to “Outperform” rating. As per Wednesday, July 26, the company rating was maintained by RBC Capital Markets. Keefe Bruyette & Woods maintained the shares of CB in report on Sunday, August 27 with “Buy” rating. On Monday, October 2 the stock rating was maintained by RBC Capital Markets with “Buy”. The rating was maintained by RBC Capital Markets on Thursday, April 27 with “Outperform”. JP Morgan upgraded the stock to “Overweight” rating in Wednesday, November 8 report. The company was maintained on Wednesday, July 5 by Keefe Bruyette & Woods. The firm has “Neutral” rating given on Tuesday, November 15 by Goldman Sachs. See Chubb Ltd (NYSE:CB) latest ratings:

08/11/2017 Broker: J.P. Morgan Rating: Buy Upgrade
08/11/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
01/11/2017 Broker: UBS Rating: Buy Old Target: $160 New Target: $169 Maintain
30/10/2017 Broker: Citigroup Rating: Neutral Old Target: $167 New Target: $173 Maintain
27/10/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $153.0 Maintain
27/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $167.0 Maintain
02/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $165.0 Maintain
27/09/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $153.0 Maintain
19/09/2017 Broker: UBS Rating: Buy Old Target: $161 New Target: $160 Maintain
27/08/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $155.0 Maintain




Wedbush Securities Inc increased Glaxosmithkline Plc (GSK) stake by 30.96% reported in 2017Q2 SEC filing. Wedbush Securities Inc acquired 9,848 shares as Glaxosmithkline Plc (GSK)’s stock rose 5.47%. The Wedbush Securities Inc holds 41,657 shares with $1.80 million value, up from 31,809 last quarter. Glaxosmithkline Plc now has $84.59 billion valuation. The stock rose 0.03% or $0.01 reaching $34.99 per share. About 94,698 shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since November 15, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.

Chubb Limited is a holding company. The Company, through its subsidiaries, provides a range of insurance and reinsurance services and products to clients around the world. The company has market cap of $69.39 billion. The Company’s divisions include North America Commercial property and casualty Insurance, North America Personal P&C Insurance, North America Agricultural Insurance, Overseas General Insurance, Global Reinsurance and Life Insurance. It has a 17.92 P/E ratio. It offers commercial insurance products and service offerings, such as risk management programs, loss control, and engineering and complex claims management.

Investors sentiment increased to 1.14 in 2017 Q2. Its up 0.14, from 1 in 2017Q1. It is positive, as 1 investors sold Chubb Ltd shares while 6 reduced holdings. 0 funds opened positions while 8 raised stakes. 668,785 shares or 9.32% less from 737,533 shares in 2017Q1 were reported. Covington Mngmt accumulated 1.01% or 85,995 shares. Penobscot Inv Com accumulated 42,479 shares. Rowland Investment Counsel Adv has 0% invested in Chubb Ltd (NYSE:CB). Fruth Investment Management holds 0.56% or 8,224 shares. Eqis Cap Mgmt, a California-based fund reported 9,775 shares. Cibc holds 0.2% or 130,977 shares. Benedict Finance Advisors reported 17,191 shares stake. 208,145 were reported by Axiom Investors Limited Company De. Baldwin Investment Management Ltd Liability Co stated it has 4,375 shares or 0.26% of all its holdings. Hudson Valley Investment Advisors Inc Adv holds 0.84% or 20,916 shares. Vantage Investment Ltd Liability Co accumulated 231 shares. Connors Investor Services stated it has 79,698 shares or 1.82% of all its holdings. Cleararc Cap holds 0.27% of its portfolio in Chubb Ltd (NYSE:CB) for 11,450 shares. Jolley Asset Mngmt Limited stated it has 200 shares or 0.02% of all its holdings. Gemmer Asset Mgmt Lc reported 202 shares.

About 11,421 shares traded. Chubb Ltd (NYSE:CB) has risen 10.92% since November 15, 2016 and is uptrending. It has underperformed by 5.78% the S&P500.

Among 15 analysts covering GlaxoSmithKline (NYSE:GSK), 6 have Buy rating, 1 Sell and 8 Hold. Therefore 40% are positive. GlaxoSmithKline had 23 analyst reports since September 8, 2015 according to SRatingsIntel. The stock has “Buy” rating by Bryan Garnier & Cie on Wednesday, January 27. The rating was maintained by J P Morgan Chase Co with “Neutral” on Friday, June 16. The rating was downgraded by Bank of America to “Hold” on Thursday, October 26. The rating was upgraded by Bank of America to “Neutral” on Tuesday, September 8. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Neutral” rating given on Wednesday, April 26 by JP Morgan. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Buy” rating given on Thursday, October 20 by Investec. The firm has “Buy” rating given on Friday, May 26 by Berenberg. Morgan Stanley downgraded the shares of GSK in report on Friday, September 8 to “Underweight” rating. The rating was downgraded by Citigroup to “Neutral” on Wednesday, July 5. Argus Research maintained the shares of GSK in report on Friday, August 12 with “Buy” rating.

Wedbush Securities Inc decreased Wells Fargo & Co New (NYSE:WFC) stake by 6,737 shares to 82,851 valued at $4.59M in 2017Q2. It also reduced Unifi Inc New (NYSE:UFI) stake by 13,788 shares and now owns 192,332 shares. Ggp Inc was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.